Eleveld model-guided dosing

Phase 3

SSeoul National University Hospital

Eleveld model-guided dosing is one of 3 therapeutic programs targeting Remimazolam. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

RemimazolamNot yet recruiting

RemimazolamPhase 3

Not yet recruiting

Competition

Competitive Landscape

5 competitors in Remimazolam

#DrugCompanyPhaseTrials

Anerem

AAcacia Pharma Ltd

Approved

16 2

Eleveld model-guided dosing

SSeoul National University Hospital

Phase 3

1 3

Romazicon

CConrado Roberto Hoffmann Filho

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

ApprovedNot yet recruiting

Remimazolam

NCT07675850

Clinical

Trials by Indication[1]

Remimazolam1 trial

Comparison of Efficacy and Safety Between Eleveld PK/PD Model-based Dosing and Standard Dosing During General Anesthesia

Not yet recruiting·SSeoul National University Hospital·Approved·NCT07675850·68 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Eleveld model-guided dosing. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Eleveld model-guided dosing. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Seoul National University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: SSeoul National University Hospital

Eleveld model-guided dosing

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Remimazolam1 trial

References

Drug Info

Quick Facts

Related News